Objectives: Significant effort has been expended over the past decade to reduce racial disparities in breast cancer care. Whether disparities in receipt of appropriate radiotherapy care for breast cancer persisted despite these efforts is unknown, as is the impact of being eligible for Medicare. We therefore investigated trends in racial differences by age in postbreast lumpectomy radiation therapy (PLRT) from 2004 to 2009.
P roper receipt of radiotherapy for breast cancer is an important public health issue, given that breast cancer is the most commonly diagnosed solid cancer in women in the United States. 1 Radiation therapy after lumpectomy or partial mastectomy is standard of care across the United States for women under the age of 70 with early, invasive breast cancer, and reduces local cancer recurrence by about two thirds. 2, 3 Considering its importance, there have been several efforts to improve access and quality of care. 4 These efforts to improve access to breast cancer radiotherapy were motivated in part by racial disparities in access to cancer care that predate the current decade. 5, 6 In particular, although the use of breast conservation surgery such as lumpectomy has increased, the requisite use of postlumpectomy radiation therapy (PLRT) has varied by race. 7, 8 For example, from 1992 to 2002, 77.8% of African American patients compared with 85.8% of white patients underwent radiation after lumpectomy. 5 There was also evidence to suggest that the disparity gap had increased slightly during the same time period. 9 There have been efforts to improve cancer care over the last 2 decades, such as the NIH Minority-Based Community Clinical Oncology Program founded in 1990 to improve minority participation in clinical trials and deliver best care practices in the community. 10 Also, the NIH Centers for Population Health and Health Disparities 11 was designed to support interdisciplinary research examining biological, social, and physical environmental factors related to health disparities since 2003. Yet, in light of these efforts, whether disparities in the receipt of appropriate breast cancer care persisted is unknown and is an important question to address. Therefore, we investigated differences in the trend in PLRT from 2004 through 2009 for different races and age groups as a measure of receipt of appropriate cancer care.
MATERIALS AND METHODS

Study Design and Data Source
We conducted a retrospective observational cohort study using the Surveillance, Epidemiology and End Results (SEER) registry database. The SEER registry is sponsored by the National Cancer Institute and records incident cancer diagnoses in 16 states and metropolitan areas covering about 26% of the US population. 12 
Study Population
Using data from the SEER database, we identified 150,813 women diagnosed from January 1, 2004 to December 31, 2009 with stage I (based on AJCC, sixth edition) invasive ductal or lobular breast cancer who received lumpectomy as primary definitive treatment. We used 2009 as the most recent year with available SEER data and included study years up to 6 years prior for current trends. Women under the age of 40 and over the age of 85 were excluded given that extremes of age (N = 6308). Exclusion criteria were as follows: histology other than invasive ductal or lobular carcinoma and their variants (N = 13,375), diagnosis by autopsy or death certificate (N = 847), secondary malignancies (N = 35,724), male sex (N = 661), or bilateral breast cancers (N = 18). Thus identifying 93,880 women. Among these patients, we further excluded women who were recorded by the SEER cancer registrars as having received treatment other than lumpectomy (N = 24,156), such as mastectomy, or who received neoadjuvant radiation therapy or nonconventional radiation therapy such as isotopes (N = 2600). Thus, we identified a final cohort of 67,124 patients who were candidates for PLRT. The study cohort of 67,124 women, included women who were 40 to 85 years with stage I breast cancer who either received (1) no radiotherapy; or (2) external beam radiotherapy (EBRT), brachytherapy, or intraoperative radiotherapy. Of the 67,124 women, 14,022 (20.9%) received no adjuvant radiotherapy, 48,955 (73%) received EBRT, and 4107 (6.1%) received either brachytherapy or intraoperative radiotherapy.
When we categorized patients by age, we a priori categorized age groups as 40 to 64 years, 65 to 69 years, and 70 years and older. These categories were defined to distinguish 3 populations of women: (1) patients aged 40 to 64 (women who were candidates for PLRT but were not typically eligible for Medicare, and thus more likely to be dependent on private insurance, be uninsured, or enrolled in Medicaid); (2) patients aged 65 to 69 (women for whom PLRT would be indicated in almost all clinical situations and who were eligible for Medicare); and (3) patients aged 70 to 85 (women for whom PLRT would be indicated in most, but not all, clinical situations and were eligible for Medicare).
Construction of Variables
The primary outcome was recorded receipt of PLRT. SEER records the order of surgery and radiotherapy, and the general type of radiation delivered such as external beam, brachytherapy, or intraoperative radiotherapy. SEER records radiation that has occurred as part of initial treatment, roughly within 6 months after diagnosis. Race was categorized by SEER as white, black (African American), Asian American/ Pacific Islander, Native American/Alaskan Native, and Other/ Unknown Race. Estrogen receptor (ER) status was recorded as positive, negative, or borderline/unknown. Marital status was recorded as married, unmarried, or unknown/unrecorded. For all analyses, 2004 year of diagnosis was used as our referent year.
Analysis
We compared the frequency of PLRT receipt across covariates using the w 2 test. The Cochran-Armitage test was used to assess the significance of trends in PLRT among age and race groups over the 6 years. To analyze all variables that were associated with receipt of PLRT, with variables of interest being race and year of diagnosis, we performed both univariate analysis and multivariable logistic regressions. To analyze whether factors associated with recorded receipt of PLRT were different based on Medicare eligibility and potential clinical benefit, we repeated these models among women 40 to 64 years, women 65 to 69 years, and women 70 to 85 years of age separately. We tested the interaction term between race categories and diagnosis year in the overall model and in the models stratified by age group. We also tested the interaction term between race categories and age groups in the overall model as well.
RESULTS
Among the 67,124 women with stage I invasive breast cancer who received a lumpectomy as their primary definitive treatment, 79% were recorded as having received PLRT (Table 1) . Overall, the proportion of patients with stage I invasive breast cancer who received PLRT decreased slightly but significantly over time, from 80.7% to 76.8% between 2004 and 2009 (P < 0.001 for trend, Table 1 ).
Variations in PLRT by age group were present over time ( Supplemental Table A , Supplemental Digital Content 1, http:// links.lww.com/AJCO/A51). There was a significant trend of younger women not eligible for Medicare (age 40 to 64) being less likely to have PLRT in 2009 compared with 2004 (79.2% in 2009 vs. 83.1% in 2004, P < 0.001 for trend). Overall, there was a decrease in PLRT from 85.1% to 80.8% also seen among women aged 65 to 69 years, who were eligible for Medicare (P = 0.007 for trend). Women over the age of 70 years had a decrease in PLRT of 4.1%, although this was not statistically significant (P = 0.338 for trend).
Among African American women, the decrease in PLRT from 2004 to 2009 was 6.9% (78.9% in 2004 vs. 72.0% in 2009, P = 0.003 for trend, Supplemental Table A , Supplemental Digital Content 1, http://links.lww.com/AJCO/A51). Among white women there was a 3.1% drop in PLRT (80.6% in 2004 vs. 77.5% in 2009, P < 0.001 for trend). The disparity in PLRT between white women and African American women therefore persisted from 1.7% in 2004 to 5.5% in 2009. Interestingly, although Asian women initially had the highest rates of PLRT (85.9% in 2004), they had a significant decrease over time with a 9.7% drop over the 6 years of study (P < 0.001 for trend).
When looking within each age group separately over time, lower rates among African American patients were present in all years most consistently for younger women aged 40 to 64 ( Fig. 1A In multivariable logistic regression, being diagnosed in more recent years was associated with a lower odds of recorded PLRT (odds ratio [OR], 0.91 in 2005, P = 0.007 to OR, 0.74 in 2009, P < 0.001; Table 2 ). African American race (vs. white) was associated with lower odds of recorded PLRT (OR, 0.76; 95% confidence interval [CI], 0.70-0.81). Older patients (aged 65 to 69) had higher recorded receipt of PLRT, in comparison with younger patients 40 to 64 years of age (82.8% vs. 82.0%; OR, 1.09; 95% CI, 1.02-1.15, P = 0.007). ER-negative status and not being married were associated with lower rates of PLRT.
An examination of the interaction term between race and year of diagnosis showed no statistically significant race by year effect (data not shown). In examining the interaction between race and age groups in the receipt of PLRT, there was a positive interaction between being African American and over age 70 for receipt of PLRT. This interaction perhaps indicated that the disparity in receipt of PLRT was greater among younger age African Americans in contrast to older African Americans being of Medicare-eligible age. Second, being Asian and age 65 to 69 years and being Asian and over age 70 had a positive interaction. These interactions perhaps indicate that the impact of being Medicareeligible age is significantly greater for Asian patients. The interactions did not change the final multivariable model in terms of which variables were significant or nonsignificant, and thus were not included in the final model for clarity.
Finally, in multivariable logistic regression of subsets of age groups, we found that diagnosis during more recent years was associated with lower rates of PLRT across all age groups, especially among women aged 40 to 65 and 65 to 69. Among women aged 40 to 64 years, African American race (OR, 0.71; 95% CI, 0.64-0.78) and Asian race (OR, 0.83; 95% CI, 0.75-0.92) were associated with lower rates of PLRT, but differences were not statistically significant in the analysis of women aged 65 to 69 years when compared with white women (Table 3) . Native Americans aged 65 to 69 were much less likely to have recorded PLRT (OR, 0.25; 95% CI, 0.11-0.58). Finally, African American women over 70 years of age were also less likely to receive PLRT compared with white women (OR, 0.84; 95% CI, 0.73-0.97).
DISCUSSION
During 2004 to 2009, the rate of standard of care PLRT decreased by a small but significant percentage (3.9%) among all women. Moreover, we found that disparities between African American and white women in receipt of PLRT persisted. For all races, women aged 65 to 69 who are traditionally insured by Medicare were more likely to receive PLRT in comparison with younger women. The trend of decreased rates of PLRT in women under the age of 70 is of particular concern given the incidence of breast cancer in the United States. Approximately 60,000 to 80,000 women are diagnosed with stage I cancer in the United States every year. 1, 13 Extrapolating an absolute decrease of 3.9% in the receipt of PLRT to this number of patients means that an estimated 2000 women each year who should receive standard of care postlumpectomy radiation therapy may not. 14 Its impact on patient outcome (recurrence and mortality) may be substantial. Assuming a 18% to 25% estimated absolute reduction in the likelihood of breast cancer recurrence risk for early-stage breast cancers for patients who undergo radiation therapy compared with those who do not, 3, 15, 16 omitting radiation therapy in these women may lead to a notable number experiencing a preventable breast cancer recurrence.
In our current study examining 2004 to more recent years, the persistence of racial disparity in the receipt of PLRT may be influenced by a number of contemporary factors including the geographic distribution of radiation facilities, disparities in access to health insurance, 17, 18 and temporal economic factors such as the recent recession. As underlying disparities in wealth among white and African American families worsened during the recession, 19 the recent economic downturn may have contributed to the persistence of racial disparities in receipt of cancer care. Indeed, although a significant interaction between race and time period was not identified, this only indicates that disparities did not worsen or improve over time-rather, they persisted.
Among women for which PLRT would be indicated in most clinical circumstances from age 40 to 64 and 65 to 69, our data indicated that older women aged 65 to 69 who are traditionally insured by Medicare were more likely to receive PLRT in comparison with younger women overall. It appears that being of Medicare-eligible age does have a differential impact by racial group. Although PLRT declined from 2004 through 2009 among women aged 65 to 69 and lower percentages of PLRT were seen in African American women, it appeared racial variations were minimized in comparison with other age cohorts. As noted previously in the multivariable logistic regression for women aged 65 to 69, there was no difference between African American and white women in terms of likelihood of PLRT receipt. It is possible that eligibility and access to public health insurance increases the likelihood of PLRT receipt and may be a factor to improving disparities. Among women aged 70 to 85 years for which PLRT may not always be clinically indicated, lower receipt of PLRT was to be expected. For instance, though the role of PLRT is standard of care for women under the age of 70 years, its role in some women with hormone receptor positive early invasive disease over 70 years old is uncertain. 20 Yet, racial variation persisted in this age group despite presumably equitable access to health insurance. Reasons may also be multifactorial and relate to clinical factors that may not be captured in our data set, such as comorbidity.
We acknowledge that underlying causes of disparities in health care use are multifactorial, and may include noneconomic factors as well. Disparities in the receipt of proper care can be impacted by differences in the quality of treating physicians and hospitals, 7,21 and the patient's own perceptions of the medical field. 22 Prior studies examining disparities in screening services for breast cancer have indicated that disparities are also associated with the distance patients have to travel to see their health care providers. 14 This may play a role in radiation therapy as well. For instance, factors including the density of radiation oncologists per area have been shown to influence rates of postmastectomy radiotherapy. 23 These broader systems issues emphasize the need for resources for health services influencing access or deliver of appropriate radiotherapy care.
Finally, our study has limitations. We analyzed receipt of PLRT after lumpectomy as recorded by the SEER registries. It is known that there is variable underascertainment of radiation therapy rates by SEER site. This perhaps may explain why ERnegative patients had lower rates of PLRT-as patients with triple-negative tumors may be more likely to undergo lengthy chemotherapy, potentially delaying receipt of PLRT to the point where it is not captured by the SEER registrars. Although this underascertainment may impact some measurements of PLRT, our study compares rates of PLRT from one time period to another. We find it likely that variations in the reporting of PLRT would be consistent year by year, and that measuring a trend over time is still valid. Furthermore, reporting of PLRT does not appear to vary by race. 24 If underascertainment of PLRT in SEER were to impact our study, there would have to be a systematic difference in the underascertainment of PLRT between races. Although variations by race in underacertaiment are less likely, general use of systemic therapy in breast conservation therapy has increased over the past 2 decades and may potentially contribute to variations by age. 25 Second, individual patient information on receipt of endocrine therapy is not available in SEER on patients for instance above age 70 with ER-positive status who may have elected to undergo hormonal therapy alone. Third, measures of change in socioeconomic status are not available in SEER. Thus patient-level socioeconomic factors such as income are unavailable to asses if this may perhaps contribute to disparities noted in PLRT by age or race. Finally, given the observational research design, causal inferences about the relationships between patient characteristics and PLRT cannot be made. Yet, regardless of the specific reason for disparate health care utilization either by age or race, identifying the continued trend in the recorded receipt of standard cancer care (such as PLRT) provides valuable information on the patterns of care in a broad field.
Overall, fewer patients were recorded as having undergone standard of care PLRT from 2004 to 2009. Disparities in the receipt of PLRT persisted in the years with the lowest use seen among African American women. Being of Medicareeligible age with clinical indications for PLRT increased the likelihood of PLRT receipt, and was associated with lower disparity between races. Efforts to improve access to appropriate radiotherapy are needed, as well as research into the economic and health service-related causes of persistent disparities in cancer care.
